Yechun Xu

41PUBLICATIONS
76CO-AUTHORS
PharmacogenomicsCheminformatics and quantitative structure-activity relationshipsNuclear physicsBiomolecular modelling and designPowder and particle technology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Apr 27, 2026
SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.

|Feb 27, 2026
Fusion Strategy of DNA-Encoded Libraries Drives Discovery of Allosteric Inhibitors of SARS-CoV‑2 RdRp.

Linjie Li, Xudong Wang, Peiqi Ding

|Dec 15, 2025
Author Correction: PPIA dictates NRF2 stability to promote lung cancer progression.

Weiqiang Lu, Jiayan Cui, Wanyan Wang

|Dec 13, 2025
Structure-Based Development of Ultra-Broad-Spectrum 3C-Like Protease Inhibitors.

Haixia Su, Tianqing Nie, Guofeng Chen

|Dec 12, 2025
Correction to "Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate".

Yu Zhou, Yan Fu, Wanchao Yin

|May 22, 2025
Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2.

Shulei Hu, Yumin Zhang, Chenchen Wang

Pageof 7

Frequent Collaborators

8 joint publications

Leike Zhang

6 joint publications

Hong Liu

5 joint publications

Qiang Shao

4 joint publications

Hualiang Jiang